Sona Nanotech
Dr. Strapps was most recently Chief Scientific Officer of Gemini Therapeutics, a NASDAQ-listed biotech company. Prior to that role, Dr. Strapps led Discovery at Intellia Therapeutics, the first CRISPR-Cas9 company to demonstrate in vivo gene editing. Dr. Strapps has worked in RNA therapeutics using chemically modified nucleotides at Merck & Co., Inc. He holds a Ph.D., M.Phil. and M.A. degrees from Columbia University and a BSc in Biology from McGill University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Sona Nanotech
Sona Nanotech produces high-quality, unique gold nanorod products for diagnostic tests and medical treatment applications. Their non-toxic nanorods are synthesized without CTAB and will power the next generation of lateral flow diagnostics.